X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (770) 770
Publication (65) 65
Book Review (12) 12
Book Chapter (4) 4
Conference Proceeding (4) 4
Newspaper Article (4) 4
Magazine Article (2) 2
Trade Publication Article (2) 2
Data Set (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (544) 544
humans (497) 497
statins (305) 305
cholesterol (255) 255
hypercholesterolemia (247) 247
cardiac & cardiovascular systems (207) 207
cholesterol, ldl - blood (203) 203
pharmacology & pharmacy (195) 195
low density lipoproteins (190) 190
proprotein convertase 9 - antagonists & inhibitors (188) 188
lipids (180) 180
antibodies, monoclonal - therapeutic use (175) 175
hypercholesterolemia - drug therapy (173) 173
alirocumab (168) 168
monoclonal-antibody (168) 168
anticholesteremic agents - therapeutic use (167) 167
risk factors (164) 164
hydroxymethylglutaryl-coa reductase inhibitors - therapeutic use (163) 163
density-lipoprotein cholesterol (160) 160
cardiovascular disease (158) 158
safety (158) 158
efficacy (156) 156
heterozygous familial hypercholesterolemia (155) 155
pcsk9 (152) 152
pcsk9 inhibitors (150) 150
female (145) 145
male (145) 145
subtilisin/kexin type 9 (133) 133
low density lipoprotein (127) 127
treatment outcome (127) 127
cardiovascular diseases (126) 126
familial hypercholesterolemia (123) 123
middle aged (123) 123
ezetimibe (121) 121
evolocumab (120) 120
statin therapy (120) 120
double-blind (119) 119
atherosclerosis (114) 114
reducing lipids (113) 113
cardiovascular diseases - prevention & control (110) 110
coronary-heart-disease (108) 108
lipoproteins (108) 108
proprotein convertase 9 (104) 104
clinical trials (102) 102
animals (100) 100
monoclonal antibodies (98) 98
aged (94) 94
cardiovascular (93) 93
cardiology (90) 90
proprotein convertases - antagonists & inhibitors (87) 87
ldl cholesterol (86) 86
risk (85) 85
therapy (85) 85
cardiovascular agents (82) 82
abridged index medicus (78) 78
care and treatment (78) 78
hypercholesterolemia - blood (77) 77
patients (77) 77
medicine & public health (76) 76
kexin (72) 72
ldl-c (72) 72
prevention (72) 72
subtilisin (72) 72
antibodies, monoclonal - adverse effects (69) 69
cardiovascular events (68) 68
diabetes (68) 68
dyslipidemia (68) 68
placebo-controlled trial (67) 67
medicine, general & internal (66) 66
analysis (64) 64
evolocumab amg 145 (64) 64
ldl-cholesterol (64) 64
proprotein convertase 9 - metabolism (63) 63
anticholesteremic agents - adverse effects (62) 62
cardiovascular-disease (61) 61
hyperlipoproteinemia type ii - drug therapy (61) 61
hypolipidemic agents - therapeutic use (61) 61
medical research (61) 61
drug therapy (60) 60
low-density lipoprotein cholesterol (60) 60
peripheral vascular disease (60) 60
biomarkers - blood (59) 59
adult (58) 58
drug therapy, combination (58) 58
mortality (58) 58
hydroxymethylglutaryl-coa reductase inhibitors - adverse effects (56) 56
antibodies, monoclonal - pharmacology (55) 55
research (55) 55
dyslipidemias - drug therapy (54) 54
internal medicine (54) 54
endocrinology & metabolism (53) 53
statin (53) 53
atorvastatin (51) 51
cardiovascular risk (51) 51
double-blind method (51) 51
randomized controlled-trial (50) 50
acute coronary syndromes (49) 49
health aspects (49) 49
antibodies, monoclonal - administration & dosage (48) 48
cardiovascular diseases - drug therapy (48) 48
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (757) 757
Spanish (7) 7
German (6) 6
Czech (2) 2
French (2) 2
Italian (2) 2
Russian (2) 2
Arabic (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2018, Volume 379, Issue 22, pp. 2097 - 2107
Among patients who had had an acute coronary syndrome, the risk of death from coronary heart disease, nonfatal myocardial infarction, stroke, or unstable... 
MEDICINE, GENERAL & INTERNAL | MANAGEMENT | MYOCARDIAL-INFARCTION | TASK-FORCE | EFFICACY | SAFETY | LDL | REDUCING LIPIDS | PCSK9 | MONOCLONAL-ANTIBODY | ASSOCIATION | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antibodies, Monoclonal - therapeutic use | Male | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Acute Coronary Syndrome - blood | Acute Coronary Syndrome - drug therapy | Acute Coronary Syndrome - complications | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Cardiovascular Diseases - epidemiology | Adult | Cholesterol, LDL - blood | Female | Hypercholesterolemia - complications | Aged | Acute coronary syndrome | Diagnosis | Myocardial infarction | Fees & charges | Lipoproteins (low density) | Heart attacks | Lipids | Cardiovascular disease | Angina | Apolipoprotein B | Ischemia | Heart diseases | Drug dosages | Statins | Cerebral infarction | Stroke | Subtilisin | Angina pectoris | Patients | Low density lipoprotein | Coronary artery disease | Cholesterol | Kexin | Monoclonal antibodies | Full text | Acute coronary syndromes | Cardiovascular diseases | Health risk assessment | Pharmaceuticals | Life Sciences | Human health and pathology | Cardiology and cardiovascular system
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 16, pp. 1489 - 1499
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 2019, Volume 170, Issue 4, pp. 221 - 229
Background: The ODYSSEY Outcomes (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) trial included... 
GLOBAL BURDEN | MORTALITY | MEDICINE, GENERAL & INTERNAL | THERAPY | REGIONS | VACCINATION | ISCHEMIC-HEART-DISEASE | HYPERCHOLESTEROLEMIA | PCSK9 INHIBITORS
Journal Article
American Journal of Cardiology, The, ISSN 0002-9149, 2014, Volume 114, Issue 5, pp. 711 - 715
Journal Article
The American Journal of Cardiology, ISSN 0002-9149, 12/2016, Volume 118, Issue 12, pp. 1805 - 1811
Previous individual trials of alirocumab (a PCSK9 monoclonal antibody) showed significant low-density lipoprotein cholesterol reductions with overall... 
CARDIAC & CARDIOVASCULAR SYSTEMS | THERAPY | METAANALYSIS | EFFICACY | REDUCING LIPIDS | HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA | CARDIOVASCULAR-RISK PATIENTS | OUTCOMES | 9 SERINE-PROTEASE | EZETIMIBE | ATORVASTATIN | Back Pain - chemically induced | Myocardial Infarction - epidemiology | Humans | Middle Aged | Nasopharyngitis - chemically induced | Antibodies, Monoclonal - adverse effects | Coronary Disease - epidemiology | Hypercholesterolemia - drug therapy | Diabetes Mellitus, Type 2 - epidemiology | Clinical Trials, Phase III as Topic | Urinary Tract Infections - chemically induced | Respiratory Tract Infections - chemically induced | Stroke - epidemiology | Pruritus - chemically induced | Hypercholesterolemia - epidemiology | Acute Coronary Syndrome - epidemiology | Comorbidity | Ezetimibe - adverse effects | Angina, Unstable - epidemiology | Influenza, Human - chemically induced | Anticholesteremic Agents - adverse effects | Randomized Controlled Trials as Topic | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Aged | Clinical Trials, Phase II as Topic | Stroke (Disease) | Medical colleges | Analysis | Low density lipoproteins | Atherosclerosis | Monoclonal antibodies | Health aspects | Coronary heart disease | Antilipemic agents | Studies | Confidence intervals | FDA approval | Diabetes | Pruritus | Drug dosages | Patients
Journal Article
Journal Article